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Introduction: Novitiate's License
I propose in this paper to address selected bioethical issues in Malaysia. As a newcomer
to the field of bioethics, I may perhaps be permitted a novice's naivete and license to
liberally interpret the scope of bioelhics, first in its conventional, narrower nleaning, and
then extending it to a less circumscribed notion of ethics in the social organisation of
healthcare, and in medical and public health practice .
Biotechnology and Bioethics: The Narrotper Viav
Advances in biotechnology, more specifically in reproductive technology, medical
imaging, genetic and DNA technology, and most recently, cloning of mammalian tissue
and organisms have brought to the fore pressing ethical issues in biomedical research and
rnedical practice ((lS Nationql Bioethics Advisory Contntission, 1997; Lev'orttirt, 1997)
Undoubtedly, these concerns will in time emerge in policy discourses in Asian countries
including Malaysia and Singapore (Abu Bakar (IKIM), 1998), if indeed they are not
already matters of grave concern. There is for instance apprehension that medical imaging
(e.g. ultrasonography) and selective abortion may exacerbate the already unbalanced
gender ratios and differential child survival in some populations (Serr, 1986; Karkal, 1987;
Murthi et al, 1995).
Insofar as biosafety is inseparable from bioethics, the National Advisory Commillee ort
(ienetic Manipulations (NACGM), which in 1996 published its Guidelinesfor the Release
of Genetically Modified Organisms (GMOs) irtto lhe Environment (Ministty of Science,
7'echnolopg,,, and Erwironmeril, 1996) was an early institutional expression of bioethical
concern in Malaysia.
Some llioethicol Concerns in Malaysict
Currently, much of public and governrnental concern in bioethics is centred on organ
donation and transplant, when it is not directed at biotechnological applications in
agriculture, industry and manufacturing. Religious authorities have been enlisted to argue
2the case for its ethical and moral probity (IKIM, l99n and the first human heart transplant
was successfully performed three months ago at the National Heart Institute (Institut
Jantung Negara).
These efforts come on top of earlier and less-publicised attempts at an ethical balance
between individual confidentiality and collective interest in HIV/AIDS screening and
epidemic control (Ministry of Health, 1997). Sentinel surveillance of HIV serogrevalence
among antenatal mothers, STD (sexually transmitted disease) patients, and TB patients,
conducted in an unlinked anonymous manner, have for instance grappled with issues of
informed consent and notification of tesl resuhs, but the deliberations and policy decisions
have been shrouded in official secrecy with little attempt at soliciting public inputs.
On the horizon however is a more wide-ranging issue which challenges us to consider a
Iess circumscribed perhaps more mundane definition of the scope of bioethics in
healthcare and medical practice. Going beyond even the bioethics of tobacco promotion
and marketing (competing perhaps with pharnraceuticals pricing and pesticide labelling
as the pre-eminent issues of public health ethics), is the prospect of the market as decisive
arbiter of healthcarc access.
The Etlics of Contentporary Hedthcare Refornts: Need versus Demand
The worldwide push for corporatisalion and privatisation of the public healthcare sector
enters its second decade in Malaysia amidst a currency and financial turmoil which has
seriously affected public sector spending for social services. This commitment to
dismantle the public healthcare sector continues unabated even as all manner of policy
initiatives are announced to stabilise the national economy in crisis (Citizens'Health
Initiative, I99Bb).
Still a public-private mix for the present, the healthcare sector in Malaysia has performed
creditably sincn Merdeka (independence from Britain in 1957) in ensuring access for the
vast majority of the population (Heller, 1982). 90% of Malaysian citizens live within an hour
or 5 km. of a health centre. The World Health Organisation recognises Malaysian government
healthcare as one of the most well-distributed health services in the Pacific region, indeed
second only to Cuba worldwide. Preventive and promotive primary care have contributed to
enviable vital statistics which are almost on a par with those of richer industrialised nations.
The infant mortality rate lor Peninsular Malaysia for instance is approaching that of the United
States. Most remarkably, these achievements have been attained at quite modest cost, public
sector health spending amounting to less than2.5oh ofGDP.
This healthcare system is now on the threshhold of quite profound change. The chronic
understaffing of the public healthcare sector is now confronted with investor-led interest in
the longer-term growth prospects of a market-oriented private health services industry. This
will accelerate the exodus of healthcare professionals from an already decimated public
sector, and will engender major realignments and new constellations of emerging and
colliding interests -- private hospital chains, pharmaceutical manufacture, wholesaling and
3retailing, hospital ancillary services, and insurance- and ernployer-initiated managed-care
organisations among others (Chan, I9%a; 1996b; 199n.
In this rapidly evolving situation, a key question is the future of equitable, accessible
healthcare of quality. The ethical issue that is at stake here, as elsewhere, is whether
demand, as opposed to need should increasingly be the future basis for health policy and
planning. In health policy circles, this is manifested as a struggle to defend the meaning of
fficiency as understood by the mainstream of public sector health planning :
[Need, or the] capacity to benefit, rather thnn expressed demand (abilin and
willingness to pay), [is) the yardstick [for efficiency] against which the
allocation of resources should be assessed. Tltis meons that the...patterns of
morbidiry and mortaliry fand) tlrcir causes fand] rhe ffictiveness of healtlt
care technology...are factors vvhiclt sltould be taken into accouru in
assessing whether any particular configuration of hcalth resources is socially
fficient or not..... A situation in which...healtlt resources is concentrated
on a population which is willing to pay for thent, but will have little or no
measurable health benefits for them, ls /ess econonrically fficient than a
situation in whiclt the sante resources are devoted ro people with conditions
for which medical science has interveruions which are ffictive, and which
ore ot low cost. The choice between need and demand as allocative devices
is a fundamental one : eitlrcr tlrc market detennines the financing and
consumption putems for health care , or overall health status is pursued as
the object of policy. In this respect WHO's Health for All contmitmeru is a
clear statement of concern with the health stalus of the population as a
whole. Thefact thol tht poor...tend to have greater health needs/capacities
to benefit from modern health technolog means that the direction of care to
thcm slnuld be a pioity on economic fficiency grounds as well os on
grounds of social justice.
A.L. Crcese, I9X)
Workl Healtlt Organisaion
Bisnmrck's Legacy in Maloysia, with a Neoliberal Trpist
In Malaysia, it is likely that a nationol health innrailce furrcl will be established in parallel
with the corporatisation of the public hospitals, if that comes to pass.
One scenario involves farming out the management of this health insurance fund to a
profit-seeking enterprise (New Slraits T'inres, forthcoming). This is of great concern to
both healthcare professionals, and to patients and consumers (C-itizens' Health lrtitiative,
1998a). In particular, they are worried that cosl conlainnretil and ntanaged cclre (perhaps
even self-mcdication?) may become perverted as euphemisms for unwarranted
compromises in quality of healthcare, if the US experience is anything to go by (JAMA,
4Dec 3, 199n. The worst scenario would have the patient-consumer caught between the
imperatives of fee-for-service private healthcare providers on the one hand, and profit-
oriented managed care on the other (Chan, forthcoming).
Perhaps of most interest to this symposium is the future possibility of discriminatory
coverage of the at-risk population by using DNA screening for markers of disease risk.
Whether it remains hubris or not (Hubbard & Lewontin, 1996), there would be much
incentive for a managed-care organisation to fragment the client pool according to
disease-risk profiles, in hopes of increasing their commercial gain through discriminatory
premiums or even worse by excluding the allegedly high-risk sub-populations.
This may not be so far-fetched. Given our current fetish with high technology as panacea,
in particular with information technology in medicine, one can imagine the Multi Media
Supercorridor (MSC) being very receptive to detailed patient databases in healthcare
management. Indeed, among the flagship applications identifed for the MSC are the
nrultipurpose electronic healthcard and telemedicine (Chee, unpubl.). Patients' DNA
profiles fit right in with this futuristic vision of millenial medicine.
Privote Enterpise andthe Social Character of Insurance: The Demise of Community
An insurance scheme is a profoundly social undertaking. Whether in the form of a publicly
managed scheme, a co-op :urangement, or a commercially purchased policy, it is in essence a
mechanism for pooling the risk of catastrophic events faced by individuals who band together
in a collective enterprise.
It is necessarily a gyoup undertaking because it is based on the recognition that the unfortunate,
random individual, relying just on his or her resources, would be overwhelmed and unable to
cope with the catastrophe. Cross-subsidy is therefore the heart and soul of insurance, the well
subsidising the ill, with the important proviso that there is little prior indication as to who might
suffer the catastrophic event. Such is the logic and rationale which drives the system.
The logic of private enterprise however is to maximise profit. In the field of insurance this
means discrminating between risk categories, fragmenting the market into those considered at
higher risk of illness, and those at lower risk.
This is why your insurance premiums increase when you cross the risk threshhold at age 40,
and skyrockets when you enter your 60s and beyond. Family history of heritable illness, in time
to be replaced by DNA screening, will attempt even finer discrimination between risk
categories, notwithstanding the cautions of molecular geneticists, epidemiologists and ethicists
most familiar with the limitations of the emerging technology (Hudson el al., 1995; Li et al.,
1992; Khoury et al., 1993; Nanrre, 7 December 1995; Hubbard & Lewontin, 1996). Or
more simply, just ask anyone with pre-exisitng chronic illness, or HIV seropositivity, who has
attempted to enrol in an insurance scheme
All this is understandable given the imperative of the commercial sector to turn a profit. Btil
u,hqt has happened here ? An acknowledged and necessarily social undertaking is being
5subverted by a process of fragmentation and individualisation of risk whose logical end-point is
its own antithesis . the sick to bear their own cost-burden of illness, the healthy to rejoice in
their good fortune (or good genes ?).
Is this the kind of health care system we want ? Or the kind of society we feel comfortable
living in ? What has happened to our Asian values and ethics, which put the priority of our
collective welfare above that of individualist concerns ? Is insurance, a quintessentially social
undertaking, compatible with the dictates of private enterprise ?
These are not alarmist fantasies. Other countries have taken heed of these disturbing
tendencies. In Australia, there are legislative bans on risk rating, in favor of uniform
community rating. Partial solutions will not work as evidenced by the experience of Blue
Cross/Blue Shield, who saw their younger, healthier subscribers desert to the for-profits such
as Aetna when they offered lower premiums to this low-risk group (Bodenheinter el. al.,
Ig74). Blue CrosslBlue Shield was left carrying the baby, or more accurately, the elderly, who
are intensive users of medical resources. To no one's surprise, the Blues eventually introduced
their own risk rating just to remain viable.
A recent billbefore the US Congress, cognizant of the implications of human genome research,
specifically sought a ban on the use of DNA screening as a tool for risk rating in the insurance
industry. Dr. Francis Collins, co-discoverer of the cysticfbrosis gene and culrent Director of
the US National Center for Human Genome Research, urged the bill's sponsors, Senators
Nancy Kassebaum and Edward Kennedy to explicitly disallow DNA screens (Nature, 11
Mqrch tgg6). The subsequent compromise however lirnited it only to a ban on the use of
genetic information in health insurance for workers who were in transition between jobs or
employment status (Nature, I Augusl 1996). The struggle for more comprehensive protection
against genetic discrimination continues with Congresswoman Louise Slaughter's bill, currently
in process. As drafted, this would prohibit health insurance plans from denying, refusing to
renew, cancelling or changing the terms of a health insurance policy based on genetic
information. Health plans woutd furthermore be baned from requiring genetic tests, and from
disclosing genetic information to a third party (Nantre, 7 July 199n.
In the meantime, the State of New Jersey had enacted the most sweeping protections against
genetic discrimination among US state legislatures. Noteworthy among the anti-discrimination
advocates were the biotechnology and phannaceutical industry lobbies. Their principal
objection to an earlier draft of the bill centred on a clause which declared individuql genomic
irtformation to be individual, private propcrty, with obvious implications for royalties and
other benefits. Once this had been overcome, they willingly allied with the anti-insurance
forces to push through the bill, fearing that patients would avoid DNA screening in the absence
of explicit protections. As Paul Billings, an expert on genetic discrimination noted, "We ot'e
recogptizing how inrportant an environmenl of tton4isa'iminalion is lo mmimise lhe benefits
of this technlogy", curc| nrore to the point,.sales. George Annas, professor of law and public
health at Boston Univeisity nonetheless found il "hizarre that other people cmt owtt your
genetic inforntaliott, hut you can'f' (Namre, 2l Not'embcr 1996).
6Privatisation An Asian Value?
The lack of clear policy statements by Malaysian (and Singaporean) authorities, on thejoint implications of biomedical and informational technologies, adds to the mounting
anxiety over the future accessibility of healthcare. This could be particularly worrisome in
a Singaporean context which in the recent past has officially sanctioned "posilive " and
"negative" eugenics in its national population planning policies (see Designer Genes,
1984: Chan, 1984).
As a closing observation, it would not be inappropriate at a symposium on ethics and
ethical values to note the irony of Asian values in cohabitation with privatisation. The
demise of community that comes along with the privatisation of what are unavoidably
communal support systems, the abdication of mandated communal responsibility,
euphemistically labelled a " re-invention of Sovernmeru" , is surely a very un-Asian
abandonment of communal solidarity. That this should be most stark in Malaysia, arguably
the most aggressively privatising of Third World countries (Jomo, 199r, while
simultaneously the most vocal of Asian values protagonists, is an astonishing commentary
on the state of public discourse in Malaysia.
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